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Middle East respiratory syndrome (MERS) represents an important respiratory disease 
accompanied by lethal outcome in one third of human patients. In recent years, several 
investigators developed protective antibodies which could be used to prevent prospective human 
epidemics. In the current study, eight human monoclonal antibodies (mAbs) with neutralizing and 
non-neutralizing capabilities, directed against different epitopes of the MERS-coronavirus (MERS-
CoV) spike (MERS-S) protein, were investigated with regard to their ability to 
immunohistochemically detect respective epitopes on formalin-fixed paraffin-embedded (FFPE) 
nasal tissue sections of MERS-CoV experimentally infected alpacas. The most intense 
immunoreaction was detected using a neutralizing antibody directed against the receptor binding 
domain S1B of the MERS-S protein, which produced an immunosignal in the cytoplasm of ciliated 
respiratory epithelium and along the apical membranous region. A similar staining was obtained 
by two other mAbs which recognize the sialic acid-binding domain and the ectodomain of the 
membrane fusion subunit S2, respectively. Five mAbs lacked immunoreactivity for MERS-CoV 
antigen on FFPE tissue, even though they belong, at least in part, to the same epitope group. In 
summary, three tested human mAbs demonstrated capacity for detection of MERS-CoV antigen 
on FFPE samples and may be implemented in double or triple immunohistochemical methods. 
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Middle East respiratory syndrome coronavirus (MERS-CoV) is a novel lineage C betacoronavirus, 
which was first identified in a patient from the Kingdom of Saudi Arabia in June 2012 (Zaki et al., 
2012). As of May 2019, MERS-CoV has been detected in 27 countries and infected more than 
2,300 patients (World Health Organization (2019) Middle East respiratory syndrome coronavirus, 
available at https://www.who.int/csr/don/24-April-2019-mers-saudi-arabia/en/). Although the 
disease vanished almost completely from headlines and newspapers, it is still a potential threat 
to human health since approximately one third of all affected patients succumb to acute 
respiratory distress syndrome and renal dysfunction (Zumla et al., 2015). 
Even though MERS-CoV is most likely derived from an ancestral reservoir in bats (Corman et al., 
2014; Cui et al., 2013; de Wit and Munster, 2013; Memish et al., 2013; Munster et al., 2016; van 
Boheemen et al., 2012), transmission to humans occurs mainly via dromedaries, which represent 
a major reservoir for the virus in large parts of the Middle East, the Canary Islands, Africa, and 
Southern Asia (Falzarano et al., 2017; Haagmans et al., 2014; Hemida et al., 2017; Saqib et al., 
2017). Infection has also been demonstrated in farmed alpacas from a region of Qatar where 
MERS-CoV is endemic (Reusken et al., 2016), but not in any other livestock species (Reusken et 
al., 2013). Recently, experimental inoculation of pigs and llamas with MERS-CoV resulted in a low 
to moderate/high levels of viral replication and shedding, respectively (de Wit et al., 2017; 
Vergara-Alert et al., 2017). Similarly, minimal virus shedding was detected in goats, sheep, and 
horses after experimental infection, but only goats developed neutralizing antibodies (Adney et 
al., 2016). Due to the close interactions of humans with potentially susceptible and contagious 
livestock species in certain parts of the world, the development of an effective vaccination 
strategy against MERS-CoV was proposed early after its initial discovery and was recently followed 
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up by the development of protective antibodies by different protocols (Agrawal et al., 2016; Corti 
et al., 2015; Houser et al., 2016; Jiang et al., 2014; Johnson et al., 2016; Li et al., 2015; Pascal et 
al., 2015; Qiu et al., 2016; Tang et al., 2014; Widjaja et al., 2019). Widjaja and colleagues (2019) 
developed a set of protective neutralizing and non-neutralizing human monoclonal antibodies 
(mAbs) which target different epitopes of the MERS-CoV spike (MERS-S) protein. 
In the present study, these mAbs were tested for immunohistochemsitry to detect respective 
epitopes on formalin-fixed paraffin-embedded (FFPE) nasal tissue sections of MERS-CoV infected 
alpacas. Immunohistochemistry is a well-established and powerful method which is frequently 
used for diagnostic purposes and evaluation of animal experiments. Simple protocols allow 
precise correlation between the presence and severity of lesions and the amount of viral antigen 
in the respective localization (Duraiyan et al., 2012). Even though there are several mAbs and 
polyclonal antibodies available for the detection of the MERS-CoV nucleocapsid and spike protein 
on FFPE tissue (Haverkamp et al., 2018), these antibodies are all derived from rabbits and mice, 
respectively (https://www.biocompare.com, accessed March 11, 2019). However, for double or 
triple immunohistochemistry and -fluoresence labeling, it can be useful to have access to epitope-
specific antibodies from different species, which can be used to visualize viral antigen in tissue 
sections. It was therefore the aim of the present study to evaluate the suitability of different 
human anti-MERS-S mAbs for detection of the respective antigen on FFPE material. 
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2. Materials and methods 
2.1. Human monoclonal antibodies 
The development of the eight diverse human mAbs directed against different epitopes of MERS-
S protein has been published previously (Widjaja et al., 2019). Shortly, generation of anti-MERS-
S H2L2 mAbs was achieved by recurrent immunization of transgenic H2L2 mice, which encode the 
human immunoglobulin variable regions, with the respective antigens and adjuvants (for 
preparation of antigens see original publications (Li et al., 2017; Mou et al., 2013; Walls et al., 
2016; Widjaja et al., 2019). At day 74, four days after the last application, spleen and lymph nodes 
were harvested and hybridoma cell lines were generated using the SP2/0 myeloma cell line. For 
production of recombinant mAbs, cDNA’s encoding the variable heavy and light chain regions of 
anti-MERS-S H2L2 mAbs were cloned into expression plasmids containing the human IgG1 heavy 
chain and Ig kappa light chain constant regions, respectively. Recombinant human anti-MERS-S 
mAbs were produced in HEK-293T cells following transfection. Antibodies were purified from 
supernatants and were screened for MERS-S reactivity and neutralizing capacity. Eight different 
mAbs (Table 1) were selected based on epitope distribution and neutralizing capacity.  
2.2. Tissue 
Formalin-fixed tissue of nasal turbinates from two experimentally infected alpacas was obtained 
from an animal trial recently implemented at the Research Center for Animal Health (Centre de 
Recerca en Sanitat Animal, CReSA, Barcelona, Spain). The mucosa was carefully removed from 
underlying bone and embedded in paraffin according to a routinely used protocol. Serial sections 
of 4 µm thick were mounted on coated glass slides (Superfrost Plus®, Menzel Co.) and the first 
section was stained with HE for evaluation by light microscopy and subsequent sections were 
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processed for immunohistochemistry. For negative control, nasal turbinate of a non-infected 
alpaca (collected during routine necropsy at the Department of Pathology, University of 
Veterinary Medicine Hannover, Germany) was used. The animal died due to cachexia related to 
non-respiratory disease. 
2.3. Immunohistochemistry 
Sections were dewaxed in Roticlear® (Roth C. GmbH & Co. KG) and subsequently rehydrated in 
isopropanol and 96% ethanol (Roth C. GmbH & Co. KG). Endogenous peroxidase activity was 
blocked by incubation of sections in 85% ethanol with 0.5% H2O2 (VWRTM International GmbH) 
for 30 min at room temperature and antigen retrieval was performed by incubation in citrate 
buffer (2.1 g citric acid monohydrate in 1 l distilled water, adjusted with NaOH to pH = 6.0) for 20 
min in a microwave (800 W). In a preliminary experiment two of the eight antibodies (1.10f3 and 
1.2g5) were additionally tested without pretreatment and with enzymatic digestion by Proteinase 
K antigen retrieval solution (Merck KGaA) according to the manufacturer’s protocol. All sections 
were transferred to Shandon CoverplatesTM (Thermo Electron GmbH) and nonspecific binding was 
blocked by inactivated 20% goat serum diluted in phosphate buffered saline (PBS) including 1% 
bovine serum albumin (BSA; PBS/BSA) for 30 minutes. Afterwards sections were incubated with 
the primary antibody (1.2g5, 1.6c7, 1.10f3, 1.6f9, 4.6e10, 7.7g6, 3.5g6 and 1.8e5) in their 
respective dilution (Table 1) for 90 min at room temperature and the secondary biotinylated 
antibody diluted in PBS (1:200) was added. Incubation for 60 min at room temperature was 
followed by treatment with the avidin-biotin-peroxidase complex (Vectastain ABC Kit Standard, 
VectorLaboratories) according to the manufacturer’s protocol. Visualization of the reaction was 
achieved by addition of chromogen 3,3-diaminobenzidine tetrahydrochloride (DAB, 0.05%, Sigma 
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Aldrich Chemie GmbH) and 0.03% H2O2. Sections were finally slightly counterstained with Mayer’s 
hematoxylin (Roth C. GmbH & Co KG). For positive control and elucidation of virus distribution, 
additional sections were stained with two different commercially available, previously published 
monoclonal mouse and polyclonal rabbit anti-MERS-CoV nucleocapsid antibodies (Sino Biological 
Inc.; Haagmans et al., 2016; Haverkamp et al., 2018), respectively. For negative controls, the 
primary antibody was replaced by ascites fluid from Balb/c mice (1:1,000) and normal rabbit 
serum (1:3,000), respectively. Moreover, all antibodies were applied to tissue of a non-infected 
alpaca (section 2.2). 
 
3. Results and Discussion 
Evaluation of HE stained slides by light microscopy revealed a mild to moderate, multifocal, 
lymphoplasmahistiocytic and suppurative rhinitis characterized by low numbers of intraepithelial 
neutrophils and lymphocytes and infiltration of the lamina propria and submucosa by low to 
moderate numbers of lymphocytes, single plasma cells, and macrophages (Fig. 1A, B). These 
findings are reminiscent of previous observations in other large animal species though lesions in 
alpacas are relatively mild and lack the necrotizing component that has been described for 
dromedaries, llamas, and pigs (Adney et al., 2014; Haagmans et al., 2016; Vergara-Alert et al., 
2017). The commercially available monoclonal and polyclonal anti-MERS-CoV nucleocapsid 
antibodies, which were used as positive controls, revealed a strong intracytoplasmic and cilia-
associated staining pattern in numerous cells (Fig. 1C, D) according to formerly published results 
(Haagmans et al., 2016; Haverkamp et al., 2018). A specific staining was absent in all negative 
controls as expected. 
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For evaluation of human mAbs by immunohistochemistry, two of the tested antibodies (1.2g5 
and 1.10f3) were applied in three different dilutions and three different pretreatments in a 
preliminary experiment to identify the best method for the use of human mAbs on FFPE tissue 
(Table 1). As a result, heat-induced antigen retrieval and application of the antibody to the lowest 
dilution revealed the best staining effects. According to these results, all other antibodies (1.6c7, 
1.6f9, 4.6e10, 7.7g6, 3.5g6, 1.8e5) were tested with heat-induced antigen retrieval and in the 
lowest dilution.  
The use of the 1.2g5 antibody in a 1:5 dilution with heat-induced antigen retrieval showed the 
strongest signal of all tested non-commercially available antibodies. Detected antigen was 
present multifocally in the cytoplasm of ciliated respiratory epithelium and segmentally along the 
apical membranous region of few infected cells (Fig. 2A). The observed staining pattern was 
comparable to descriptions by others investigating the distribution of MERS-CoV in tissue sections 
of different infected animal species (Adney et al., 2014; Haagmans et al., 2016; Haverkamp et al., 
2018; Vergara-Alert et al., 2017) but the number of labeled cells was considerably lower. Staining 
with the same antibody without pretreatment revealed a similar distribution of viral antigen in a 
comparable number of cells but a less prominent expression pattern (Fig. 2B), which is most likely 
linked to the lack of antigen unmasking which takes place during antigen retrieval (Shi et al., 
2011). Detection of MERS-CoV antigen by the 1.2g5 antibody was almost completely absent with 
pretreatment by enzymatic digestion in all three dilutions, resulting only in a pale brownish signal 
interpreted as non-specific background staining (data not shown). The antibody 1.10f3 showed a 
strong non-specific background staining in all dilutions and pretreatments. A moderately intense 
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antigen-specific signal was detected multifocally in cilia of few cells using the lowest dilution and 
citrate pretreatment (Fig. 2C). 
Of these six remaining antibodies (1.6c7, 1.6f9, 4.6e10, 7.7g6, 3.5g6, 1.8e5), only antibody 1.6c7 
showed a mild multifocal staining of cilia accompanied by a strong background reactivity (Fig. 2D). 
The other five antibodies did not reveal any recognizable specific staining of MERS-CoV antigen 
on FFPE tissue along with no to very mild (1.6f9, 4.6e10, Fig. 3A, B), mild (7.7g6, 1.8e5, Fig. 3C, D) 
and strong (3.5g6, Fig. 3E) non-specific background staining. By contrast, all antibodies displayed 
a distinct signal by immunofluorescence staining of MERS-CoV-infected Huh-7 cells in culture 
(Widjaja et al., 2019). Possible explanations for the lack of immunoreactivity on FFPE tissue 
include effacement of conformational epitopes by formalin fixation and/or antigen retrieval 
protocols (Smedley et al., 2007). 
All tested antibodies in the present study were directed against MERS-S and belong to six distinct 
epitope groups that interfere with three critical entry functions in vivo. In particular, 1.2g5, 7.7g6, 
1.6f9, 1.8e5, and 4.6e10 are neutralizing antibodies directed against the receptor binding domain 
S1B of the MERS-S protein (Widjaja et al., 2019), which facilitates virus binding to the DPP4 
receptor on the host cell surface (Mou et al., 2013; Raj et al., 2013). The neutralizing antibodies 
1.6c7 and 3.5g6 bind to the ectodomain of the membrane fusion subunit S2 which mediates 
fusion of the viral and cellular membranes (Li et al., 2017; Widjaja et al., 2019). By contrast, 
antibody 1.10f3 is a non-neutralizing antibody that recognizes the sialic acid-binding domain 
(Widjaja et al., 2019). Since one antibody of each functional group was able to detect viral antigen 
on FFPE tissue, the suitability for use in immunohistochemistry cannot be predicted from its 
function in vivo. 




The present study shows that three tested human mAbs, designated 1.2g5, 1.10f3 and 1.6c7, are 
suitable to detect MERS-CoV antigen on FFPE tissue sections of experimentally infected alpacas, 
though to a limited extend. The best immunolabelling results for all three antibodies were 
achieved at the lowest dilution (1:5) with heat-induced antigen retrieval. However, results 
demonstrate that the suitability of the antibodies was unrelated to the function of their target 
epitopes in vivo and that commercially available monoclonal and polyclonal anti-nucleocapsid 
antibodies generally appear more suitable to detect MERS-CoV antigen on FFPE sections in 
routine diagnostics. However, for certain purposes such as double or triple 
immunohistochemistry, human mAbs might represent a promising alternative.  




Figure 1. Representative HE findings in respiratory epithelium of the nasal turbinates of MERS-
CoV-infected alpacas and immunohistochemical reactions of the commercially available 
positive controls for comparison. (A) Multifocal infiltration of lamina propria and submucosa by 
moderate numbers of lymphocytes, macrophages and single neutrophilic granulocytes (asterisk). 
(B) Exocytosis of single neutrophilic granulocytes (grey arrow). (C and D) Abundant viral antigen 
was detected multifocally in the cytoplasm and along the apical membranous region of epithelial 
cells using a monoclonal mouse (C, Sino Biological Inc.) and polyclonal rabbit anti-MERS-CoV 
nucleocapsid antibody (D, Sino Biological Inc.) with citrate pretreatment, in a dilution of 1:70 and 
1:2,000, respectively. Both antibodies exhibited a similar staining intensity. (A, B) HE staining; 
400x, (C, D) Avidin-biotin-peroxidase complex method with 3,3′-diaminobenzidine as chromogen; 
400x.  
  




Figure 2. Representative positive immunohistochemical reactions for human monoclonal 
antibodies. (A) Antibody 1.2g5 with citrate pretreatment exhibited a strong multifocal MERS-CoV 
antigen specific signal in the cytoplasm of ciliated respiratory epithelial cells (arrow) and 
segmentally along the apical membranous region (arrow heads). (B) The same protocol without 
pretreatment revealed a much fainter but similarly distributed staining of cytoplasm (arrow) and 
ciliary base (arrow heads). (C) Antibody 1.10f3 with citrate pretreatment displayed a strong 
diffuse background staining and only few positively stained cilia (arrowhead). Single 
intraepithelial plasma cells displayed a strong false positive intracytoplasmic staining (white 
arrow). (D) Antibody 1.6c7 with citrate pretreatment exhibited also a strong diffuse background 
staining and only few positive staining cilia (arrow heads). (A-D) Avidin-biotin-peroxidase complex 
method with 3,3′-diaminobenzidine as chromogen; 400x. 
  




Figure 3. Representative negative immunohistochemical reactions for human monoclonal 
antibodies. Specific staining for MERS-CoV antigen was absent for the antibodies 1.6f9 (A), 4.6e10 
(B), 7.7g6 (C), 1.8e5 (D) and 3.5g6 (E), respectively. Reactions were accompanied by mild to severe 
non-specific, intracytoplasmic background staining. (A-E) Avidin-biotin-peroxidase complex 
method with 3,3′-diaminobenzidine as chromogen; 400x. 
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1.6f9 0.23 1:5 - 
4.6e10 0.43 1:5 - 
7.7g6 0.77 1:5 - 
1.8e5 0.25 1:5 - 














1.0 1:2000 GaR-b +++ 
mc, monoclonal; MERS-CoV, Middle East respiratory syndrome coronavirus; GaM-b, goat anti-
mouse IgG biotinylated; GaH-b, goat anti-human IgG biotinylated; GaR-b, goat anti-rabbit IgG 
biotinylated; pc, polyclonal; #, antigen retrieval was performed with boiling citrate buffer, 
proteinase K and omission of pretreatment 
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